Compare Kinder Morgan Inc (KMI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs BIO-TECHNE Corp — how do they compare? Kinder Morgan Inc trades at $32.53 (market cap $71.81B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Kinder Morgan Inc is far larger — about 6.3× BIO-TECHNE Corp's market cap, and Kinder Morgan Inc pays the higher dividend (3.66%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and BIO-TECHNE Corp for 64 Days on average.
| KMI | TECH | |
|---|---|---|
Market Cap | $71.81B | $11.36B |
Volume | 16,921,908 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $34.31 | $72.61 |
52-Week Low | $25.84 | $43.31 |
Typical Hold Time | 150 Days | 64 Days |
Enterprise Value | $103.86B | $11.39B |
Dividend Yield | 3.66% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.36, up 1.7% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and consistent earnings beats, while maintaining a 19.31% net income margin. Recent news highlights the company's $6B-$7B growth pipeline and resilience in volatile energy markets.
KMI presents a compelling investment case with analyst consensus target of $37.20 (15% upside), strong dividend yield, and fee-based revenue model. Key risks include energy market volatility and high debt levels, but the company's project backlog and natural gas demand growth support positive long-term outlook.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
